ASH Preview: J&J And Legend’s CAR-T Takes Center Stage
Frontrunners Bide Their Time
While bluebird bio, Celgene and GSK prepare to file, it’s time to shine for another myeloma contender.
You may also be interested in...
The DREAMM-2 trial of the antibody-drug conjugate belantamab mafodotin in relapsed/refractory multiple myeloma patients has hit its primary endpoint, giving GSK a chance to file for approval before its BCMA rivals.
While data on Sanofi's anti-CD38 antibody isatuximab impressed at ASCO, analysts believe that the position of Johnson & Johnson's Darzalex in the multiple myeloma space is unlikely to be threatened.
Moderna is hot on the heels of Pfizer with booster data for its COVID-19 vaccine, and could benefit from its rival being first to face potential skepticism from the US FDA over booster data for its vaccine.